![]() ![]() The P-15 L bone graft substitute did not have any adverse effects on systemic health.ĬONCLUSIONS: The drug device combination P-15 L was demonstrated to be effective and save for lumbar interbody fusion as evidenced by this ovine model. ![]() At 3 months after surgery significantly denser and stiffer bone was found in the P-15 L group, whereas at 6 months, P-15 L and ICBG gave similar fusion results. There was active bone remodeling between 1 and 3 months after surgery. RESULTS: One month after surgery, there was only minor evidence of bone remodeling and residual graft material could be clearly observed within the cage. Additional systemic health monitoring was performed for the P-15 L group. Following termination at 1, 3, and 6 months after surgery, the operated segments were analyzed using micro computed tomography (♜T), histology, and destructive mechanical testing. Half of the sheep received autologous ICBG and the other half the peptide enhanced bone graft substitute (P-15 L). METHODS: Thirty skeletally mature sheep underwent lumbar interbody fusion surgery. i-FACTOR is free of many safety risks seen with other products such as ectopic bone formation and on average costs at least 30% less expensive than other drug-device combination products.OBJECTIVE: To assess the in vivo efficacy and safety of the P-15 L bone graft substitute and compare its performance to autologous iliac crest bone graft (ICBG) for lumbar interbody fusion indications. One of only two Class III FDA-PMA approved spinal bone grafts, i-FACTOR is the leading evidence-based alternative and is powered by a first of its kind molecule called P-15: Osteogenic Cell Binding Peptide. In this study i-FACTOR demonstrated high fusion rates and statistical superiority vs. See more >Ĭerapedics is an advanced orthobiologics company, enhancing the science of bone repair in orthopedic and spinal fusion procedures with i-FACTOR® Peptide Enhanced Bone Graft.Īmong 400+ spinal bone grafts on the market, spine surgeons can feel confident in choosing i-FACTOR Peptide Enhanced Bone Graft which is backed by Level 1 human clinical data from an IDE study published in Spine and Neurosurgery. Partnered with senior leadership to design organization & successfully implement talent acquisition, onboarding, training, & long-term staffing. Led HR strategy & tactics for Elanco’s entry into the Companion Animal Health business.Integral role in the transformation of HR model to HRBPs & COEs.Designed new roles, positions, organizations, job/compensation structures, competency models, & career paths.Strategized with senior leadership to design & implement robust & customized variable compensation programs.HR lead role in the redesign of external workforce (over 1000 personnel) for utilization & cost efficiencies ($10M savings).Led HR strategy & tactics for acquisition restructuring, organization design, & staffing rationalization for the global G&A functions & U.S./Canada commercial business as part of Lilly’s $5.4B acquisition of Swiss-based Novartis Animal Health.Led complex organizational change for Boulder Brands integration into Pinnacle Foods in 1st year post-acquisition.Recognized for aligning HR strategy with talent while ensuring that the required structure, capabilities, culture, & leadership are developed & in place to achieve business objectives. Have successfully managed human capital & led HR teams in Fortune 150, mid-size, & entrepreneurial organizations across varied industries including medical device, pharmaceutical, CPG/food, healthcare, animal health, & higher education. Senior level Human Resources leader with over 20 years of progressive HR experience.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |